References
- Astrom KE, Mancall EL, Richardson EP Jr. Progressive multifocal leuko-encephalopathy; a hitherto unrecognized complication of chronic lymphatic leukaemia and Hodgkin's disease. Brain 1958;81: 93–111.
- Brooks BR, Walker DL. Progressive multifocal leukoencephalopathy. Neurol Clin 1984;2:299–313.
- Holman RC, Torok TJ, Belay ED, . Progressive multifocal leukoencephalopathy in the United States, 1979-1994: increased mortality associated with HIV infection. Neuroepidemiology 1998; 17:303–309.
- Selik RM, Karon JM, Ward JW. Effect of the human immunodeficiency virus epidemic on mortality from opportunistic infections in the United States in 1993. J Infect Dis 1997;176:632–636.
- Brooks BR, Walker DL. Progressive multifocal leukoencephalopathy. Neurologic clinics 1984;2:299–313.
- Amend KL, Turnbull B, Foskett N, . Incidence of progressive multifocal leukoencephalopathy in patients without HIV. Neurology 2010;75:1326–1332.
- Mateen FJ, Muralidharan R, Carone M, . Progressive multifocal leukoencephalopathy in transplant recipients. Ann Neurol 2011;70: 305–322.
- Langer-Gould A, Atlas SW, Green AJ, . Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N Engl J Med 2005;353:375–381.
- Kleinschmidt-DeMasters BK, Tyler KL. Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis. N Engl J Med 2005;353: 369–374.
- Van Assche G, Van Ranst M, Sciot R, . Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease. N Engl J Med 2005;353:362–368.
- Berger JR. Progressive multifocal leukoencephalopathy and newer biological agents. Drug Saf 2010;33:969–983.
- Kothary N, Diak IL, Brinker A, . Progressive multifocal leukoencephalopathy associated with efalizumab use in psoriasis patients. J Am Acad Dermatol 2011;65:546–551.
- Carson KR, Evens AM, Richey EA, . Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. Blood 2009;113:4834–4840.
- FDA drug safety communication: New boxed warning and contraindication for Adcentris (brentuximab vedotin). 2012. Available from: http://www.fda.gov/Drugs/DrugSafety/ucm287668.htm#data
- Clifford DB, De Luca A, Simpson DM, . Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases. Lancet Neurol 2010;9:438–446.
- Keller-Stanislawski B. Natalizumab (Tysabri) and PML – the current figures. Presented at Transatlantic workshop: drug-related progressive multifocal leukencephalopathy. July 2011. European Medicines Agency, London.
- Garcia-Suarez J, de Miguel D, Krsnik I, . Changes in the natural history of progressive multifocal leukoencephalopathy in HIV-negative lymphoproliferative disorders: impact of novel therapies. Am J Hematol 2005;80:271–281.
- Vermersch P, Kappos L, Gold R, . Clinical outcomes of natalizumab-associated progressive multifocal leukoencephalopathy. Neurology 2011;76:1697–1704.
- Berger JR, Koralnik IJ. Progressive multifocal leukoencephalopathy and natalizumab—unforeseen consequences. N Engl J Med 2005; 353:414–416.
- Major EO. Progressive multifocal leukoencephalopathy in patients on immunomodulatory therapies. Annu Rev Med 2010;61:35–47.
- Wollebo HS, Safak M, Del Valle L, . Role for tumor necrosis factor-alpha in JC virus reactivation and progressive multifocal leukoencephalopathy. J Neuroimmunol 2011;233:46–53.
- Bellizzi A, Barucca V, Fioriti D, . Early years of biological agents therapy in Crohn's disease and risk of the human polyomavirus JC reactivation. J Cell Physiol 2010;224:316–326.
- Kumar D, Bouldin TW, Berger RG. A case of progressive multifocal leukoencephalopathy in a patient treated with infliximab. Arthritis Rheum 2010;62:3191–3195.